EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Edinburgh Molecular Imaging Appoints Bernhard Sixt as New Chief Executive Officer
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular
Edinburgh Molecular Imaging Ltd Appoints New Chairman
Roy Davis appointed as Non-Executive Chairman. Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology
NodThera Announces the Appointment of Alison Strutt PhD as Head of Finance & Operations, the Launch of its New Corporate Office in Boston and the Opening of its Laboratory in Seattle
Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships and develop deep insights into inflammasome biology to
IGEM Therapeutics Awarded “Best Start-up Biotech Company” at the 2018 OBN Awards
London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has
Epidarex Portfolio Companies Nodthera and Enterprise Therapeutics Nominated for the 2018 Pharma Intelligence Scrip Awards’ Private Financing Deal of the Year
Please see the full list of nominees and additional information regarding the awards here.
Major International FDA-led study confirms CellOPTIQ® High Content Assay as the Leading In Vitro platform to Assess Cardiotoxicity in New Drugs
Motherwell, Scotland, 27th September 2018 – Clyde Biosciences, the leader in cardiac cell function assessment, announced today that its proprietary CellOPTIQ® High Content Assay (HCA)
NodThera Announces the Appointment of Adam Keeney PhD as President and Chief Executive Officer
Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at Sanofi and prior to that at Johnson & Johnson
Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
CRESTWOOD, Ky., and WALTHAM Mass. – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through